Of the two drugs for geographic atrophy (GA) to receive FDA approval in 2023, Izervay has shown a statistically significant reduction in GA progression after 12 months of ongoing treatment. The drug demonstrated these results in two Phase 3 clinical trials. These trials also showed that GA progression began to slow as early as six months after the initial dose.
GA is an advanced form of one of the most common causes of central vision loss among older adults: age-related macular degeneration (AMD). Defined by legions of atrophied tissue, GA spreads along with AMD to affect the outer retina, the macula, and the fovea, ultimately resulting in irreversible vision loss. In fact, roughly 66 percent of people with GA are likely to become blind or seriously visually impaired without prompt treatment.
When given two milligrams of Izervay monthly, clinical trial participants experienced as much as a 35-percent reduction in GA progression within a year. This proven rate of reduction exceeds those of all other available treatments.
GA is an advanced form of one of the most common causes of central vision loss among older adults: age-related macular degeneration (AMD). Defined by legions of atrophied tissue, GA spreads along with AMD to affect the outer retina, the macula, and the fovea, ultimately resulting in irreversible vision loss. In fact, roughly 66 percent of people with GA are likely to become blind or seriously visually impaired without prompt treatment.
When given two milligrams of Izervay monthly, clinical trial participants experienced as much as a 35-percent reduction in GA progression within a year. This proven rate of reduction exceeds those of all other available treatments.